Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study by Seyed Mohamad Sadegh Mousavi-kiasary, Mahdis Bayat, Fereshteh Abbasvandi, Batoul Khoundabi, Fatemeh Mousavi, Atieh Akbari, Maryam Bagherian, Afsoon Zandi, Behnam Honarvar, Mohammad Esmaeil Akbari

Get full text

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer by Elizabeth J. Anderson, Lea E. Mollon, Joni L. Dean, Terri L. Warholak, Ayal Aizer, Emma A. Platt, Derek H. Tang, Lisa E. Davis

Get full text

Discovery of a sushi domain-containing protein 2-positive phenotype in circulating tumor cells of metastatic breast cancer patients by Kai Bartkowiak, Parinaz Mossahebi Mohammadi, Paula Nissen, Stefan Werner, David Agorku, Antje Andreas, Maria Geffken, Sven Peine, Karl Verpoort, Thomas M. Deutsch, Laura L. Michel, Andreas Schneeweiss, Verena Thewes, Andreas Trumpp, Olaf Hardt, Volkmar Müller, Sabine Riethdorf, Hartmut Schlüter, Klaus Pantel

“…Expression of SUSD2 on subsets of CTCs was validated on clinical blood samples of patients with metastatic breast cancer. SUSD2-positive CTCs could be captured specifically by a MACS-based approach. …”
Get full text

High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors by Atsushi Fushimi, Isao Tabei, Azusa Fuke, Tomoyoshi Okamoto, Hiroshi Takeyama

“…This retrospective analysis investigated the outcomes of 19 women with postmenopausal hormone-sensitive recurrent or metastatic breast cancer who received HD-TOR, defined as 120 mg daily from 2012 to 2016. …”
Get full text

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors by Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra

Subjects: “…metastatic breast cancer…”
Get full text

Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study by Akif Doğan, Nurullah İlhan, Goncagül Akdağ, Sedat Yıldırım, Mustafa Seyyar, Zeynep Yüksel Yaşar, Hande Nur Erölmez, Heves Sürmeli, Buğra Öztosun, Özlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yıldırım, Devrim Çabuk, Nedim Turan, Mahmut Gümüş

Subjects: “…premenopausal metastatic breast cancer…”
Get full text

RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer by Zhe Rong, Li Li, Fei Fei, Lailong Luo, Yang Qu

Get full text

The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer by Ting Xu, Weili Xiong, Lili Zhang, Yuan Yuan

“…The study preliminarily demonstrates that anlotinib combined with chemotherapy may be an optional recommendation for patients with HR+/HER2– metastatic breast cancer who have progressed after CDK4/6i.…”
Get full text

Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study by François-Clément Bidard, Lisa Belin, Suzette Delaloge, Florence Lerebours, Charlotte Ngo, Fabien Reyal, Séverine Alran, Sylvie Giacchetti, Michel Marty, Ronald Lebofsky, Jean-Yves Pierga

“…Introduction. In non-metastatic breast cancer patients, the REMAGUS02 neoadjuvant study was the first to report a significant impact of circulating tumor cells (CTCs) detection by the CellSearch system on the distant metastasis-free survival (DMFS) and overall survival (OS) endpoints. …”
Get full text

A patient-led survey on information and communication needs of patients with metastatic breast cancer in Ireland and Northern Ireland (CTRIAL-IE 23–05) by Siobhan Gaynor, Yvonne O'Meara, Emer Mulvaney, Rachel J. Keogh, Catherine S. Weadick, Fran J. Duane, Ann Mc Brien, Helen Greally, Mary Jane O'Leary, Ieva Teiserskyte, Isabel Beristain, Jacinta Marron, Eibhlin Mulroe, Vicky Donachie, Sarah Mc Loughlin, Seamus O'Reilly

“…Introduction: Although treatment advances have improved survival rates for patients with metastatic breast cancer (MBC), patient expressed needs have not been evaluated in Ireland to date. …”
Get full text

Retraction Note: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer by Zhe Rong, Li Li, Fei Fei, Lailong Luo, Yang Qu

Get full text

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them by L. Foffano, L. Cucciniello, E. Nicolò, I. Migliaccio, C. Noto, C. Reduzzi, L. Malorni, M. Cristofanilli, L. Gerratana, F. Puglisi

Subjects: “…Metastatic breast cancer…”
Get full text

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan by Ünal Metin Tokat, Ashkan Adibi, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Get full text

A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer by Jingshu Wang, Xiuping Lai, Herui Yao, Hui Yang, Xiaolong Cao, Xiaochen Wang, Ying Wang, Weiqi Nian, Xiaodong Zheng, Qingxiu Mai, Anding Liu, Xiaozhi Lv, Xiaoying Bi, Junyi Chen, Junyan Wu, Suiwen Ye

“…Abstract Purpose The primary objectives of this trial were aimed at exploring the pharmacokinetic profiles and the human bioequivalence of an intravenous liposomal injection of doxorubicin hydrochloride in comparison with a reference formulation in Chinese patients diagnosed with metastatic breast cancer. Methods To achieve these goals, the trial employed a randomized, open-label, two-formulation crossover dosing strategy among Chinese patients with metastatic breast cancer. …”
Get full text

Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer by Brenno Pastò, Riccardo Vida, Arianna Dri, Lorenzo Foffano, Serena Della Rossa, Lorenzo Gerratana, Fabio Puglisi

Subjects: “…Metastatic breast cancer…”
Get full text

Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial by Jianli Zhao, Yunfang Yu, Wei Ren, Linxiaoxiao Ding, Yongjian Chen, Peng Yuan, Jian Yue, Yaping Yang, Guorong Zou, Tao Chen, Jie Chai, Li Zhang, Wenjing Wu, Yinduo Zeng, Xiujuan Gui, Yangyang Cai, Simin Luo, Zhongyu Yuan, Kang Zhang, Herui Yao, Ying Wang

“…Abstract This multicenter, single‐arm, phase II clinical trial (NCT04034589) evaluated the efficacy and safety of pyrotinib combined with fulvestrant in patients with HR‐positive/HER2‐positive metastatic breast cancer who had experienced trastuzumab treatment failure. …”
Get full text

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre by Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah

“…Methods: We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. …”
Get full text

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus by Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi

Subjects: Get full text

Resolution on the results of scientific-practical conference "Clinical evidence of increasing overall survival in the treatment of metastatic breast cancer", held on 29 November 2014 under the auspices of the Department of health of Moscow by E. T. Bairamov, A. V. Belonogov, V. V. Brusnichkina, A. V. Bulakh, M. Y. Byahov, S. N. Gurov, G. G. Eremeev, N. V. Zhukov, L. G. Zhukova, L. M. Kogonia, P. V. Koposov, L. K. Ovchinnikova, V. V. Radlevich, E. A. Samyshina, A. P. Seryakov, M. D. Ter-Ovanesov, I. E. Shumskaya

“…Objectives: discussion of modern treatment options for metastatic breast cancer (MBC), the determining of the optimal treatment for subgroups of patients with poor prognosis.…”
Get full text

Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome by Khaled Abd Elaziz Ahmed Elnaghi, Hosam Ali Alghanmi, Shereef Ahmed Elsamany, Fathia Almarzoki, Mohamed Elsafty, Mohammad Jaffal

Get full text